Patents by Inventor Daria Larissa FORSTER

Daria Larissa FORSTER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20230226222
    Abstract: A method for treating a subject having a medical condition associated with inflammation and/or an unwanted immune response without an alpha1-antitrypsin (AAT) deficiency, wherein the method comprises administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells comprise an exogenous nucleic acid comprising (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 20, 2023
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20200282078
    Abstract: A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: February 25, 2020
    Publication date: September 10, 2020
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER
  • GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT)
    Publication number: 20180000969
    Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Inventors: Christine GÜNTHER, Sabine GEIGER-SCHREDELSEKER, Felix HERMANN, Ralf HUSS, Daria Larissa FORSTER